Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>m<sup>6</sup>A modification affects the pathological progress of many diseases by affecting RNA stability and translocation. YTHDC2, a m<sup>6</sup>A reader, is associated with multiple cancers; however, little is known of its role in non‐small cell lung cancer (NSCLC). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>The GEPIA, Oncomine and GEO databases were analyzed to assess expression of <i>YTHDC2</i> in NSCLC patients. Quantitative polymerase chain reaction, western blot and immunohistochemistry were used to detect YTHDC2 expression in different NSCLC cell lines (H1299, H460, H292 and A549) and patients. The effects of YTHDC2 on NSCLC cell lines (A549 and H1299) proliferation and migration were employed using CCK8 and transwell assays. The potential target RNAs of YTHDC2 were obtained from the POSTAR database. Functional enrichment analysis of YTHDC2 targeted RNAs was performed using the Metascape database. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>GEPIA, Oncomine and GEO databases showed low expression of <i>YTHDC2</i> in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patients. YTHDC2 expression was significantly decreased in different NSCLC cell lines and our clinical samples. Moreover, low expression of YTHDC2 was significantly associated with poor differentiation, lymph node metastasis, tumor size and stage. In addition, YTHDC2 could suppress the proliferation and migration ability of A549 and H1299 cell lines. Kaplan‐Meier Plotter database analysis revealed that patients with low level of YTHDC2 had a significantly poor prognosis. Finally, functional enrichment analysis of YTHDC2 targeted RNAs indicated several enriched pathways related to cancer. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>These findings elucidate that YTHDC2 suppresses tumorigenesis in NSCLC, indicating that YTHDC2 may be a promising therapeutic target for NSCLC.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key points</h3></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Significant findings of the study</h3><p>This study demonstrated that the downregulation of YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer (NSCLC).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> What this study adds</h3><p>YTHDC2 might be a promising therapeutic target for non‐small cell lung cancer (NSCLC).</p></section>

Down‐regulation of MTHFD2 Inhibits NSCLC Progression by Suppressing Cycle‐related Genes

MTHFD2 Promotes Tumorigenesis and Metastasis in Lung Adenocarcinoma by Regulating AKT/GSK‐3β/β‐catenin Signalling

Pharmacological Targeting of MTHFD2 Suppresses NSCLC Via the Regulation of ILK Signaling Pathway

Downregulation of MTHFD2 Inhibits Proliferation and Enhances Chemosensitivity in Hepatocellular Carcinoma via PI3K/AKT Pathway

Methylenetetrahydrofolate Dehydrogenase 1 Silencing Expedites the Apoptosis of Non-Small Cell Lung Cancer Cells Via Modulating DNA Methylation

MTHFD1L-Mediated Redox Homeostasis Promotes Tumor Progression in Tongue Squamous Cell Carcinoma

Downregulation of MTHFD2 Inhibits the Progression of Bladder Cancer Through PI3K/AKT Signaling Pathways

Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications

Downregulation of CISD2 Has Prognostic Value in Non-Small Cell Lung Cancer and Inhibits the Tumorigenesis by Inducing Mitochondrial Dysfunction

MTHFD2 suppresses glioblastoma progression via the inhibition of ERK1/2 phosphorylation

Downregulation of M6a Reader YTHDC2 Promotes Tumor Progression and Predicts Poor Prognosis in Non‐small Cell Lung Cancer

Transcriptional Profiling Revealed the Anti-Proliferative Effect of MFN2 Deficiency and Identified Risk Factors in Lung Adenocarcinoma

Downregulation of m 6 A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer

Silencing SHMT2 inhibits the progression of tongue squamous cell carcinoma through cell cycle regulation

Increased MTHFD2 Expression is Associated with Poor Prognosis in Breast Cancer

MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion.

P2.01-082 Transcriptional Profiling Identified the Anti-Proliferative Effect of Mitofusin-2 Deficiency and Its Risk in Lung Adenocarcinoma

Clinical Significance of Circ-Mthfd2 in Diagnosis, Pathological Staging and Prognosis of NSCLC.

NT5DC2 suppression restrains progression towards metastasis of non-small-cell lung cancer through regulation p53 signaling

Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer

Downregulation of <scp> m <sup>6</sup> A </scp> reader <scp>YTHDC2</scp> promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer